Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

This study has been terminated.
(2 DLTs had been reported from first 4 patients on lowest possible dose cohort.)
Sponsor:
Collaborators:
Cancer Research UK
AstraZeneca
Information provided by (Responsible Party):
Suzanne Rowland, Christie Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01160926
First received: July 7, 2010
Last updated: January 26, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2016
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)